The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas

BACKGROUND: The highly selective oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib has demonstrated significant activity in adult and pediatric TRK fusion cancers. In the current study, the authors describe the clinical course of children with locally advanced TRK fusion sarcoma who wer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: DuBois, Steven G., Laetsch, Theodore W., Federman, Noah, Turpin, Brian K., Albert, Catherine M., Nagasubramanian, Ramamoorthy, Anderson, Megan E., Davis, Jessica L., Qamoos, Hope E., Reynolds, Mark E., Cruickshank, Scott, Cox, Michael C., Hawkins, Douglas S., Mascarenhas, Leo, Pappo, Alberto S.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6263791/
https://ncbi.nlm.nih.gov/pubmed/30204247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31701
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados